Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist

Debendra Pattanaik1, Phil Lieberman, Pranab Das

  • 1Department of Medicine, Division of Allergy & Immunology, University of Tennessee Health Science Center, 956 Court Avenue, Memphis, TN, USA.

Future Cardiology
|August 9, 2012
PubMed

Insights

Aspirin desensitization is crucial for coronary artery disease (CAD) patients with aspirin hypersensitivity. Rapid desensitization protocols offer a more effective alternative to older methods for managing this condition.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Aspirin is a primary antiplatelet therapy for coronary artery disease (CAD).
  • Aspirin or NSAID hypersensitivity presents diverse reactions, from skin to respiratory issues.
  • Clinicians often avoid aspirin in hypersensitive CAD patients, despite its importance.

Purpose of the Study:

  • To underscore the significance of aspirin desensitization in CAD patients.
  • To elucidate the mechanisms and procedures of aspirin desensitization.
  • To introduce and evaluate recent rapid desensitization protocols.

Main Methods:

  • Review of existing literature on aspirin desensitization.
  • Description of the immunological mechanisms underlying hypersensitivity reactions.
  • Explanation of traditional and novel rapid desensitization protocols.

Main Results:

  • Aspirin desensitization is a viable option for CAD patients with hypersensitivity.
  • Rapid desensitization protocols show promise for improved efficacy and patient management.
  • Understanding the mechanism aids in managing hypersensitivity reactions.

Conclusions:

  • Aspirin desensitization is essential for CAD patients unable to tolerate aspirin.
  • Rapid desensitization protocols represent an advancement over older methods.
  • Further research into desensitization protocols can optimize CAD patient care.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...